Business Daily Media

Business Marketing

.

Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

  • Written by ACN Newswire - Press Releases
ADELAIDE, AU, Mar 12, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19.

Atossa Therapeutics, Inc....

Popular

Data is out of the bag, so how do we protect customers now?

Data is out of the bag and there is no way to stop the spread of information. So, how can we protect our identities from theft and ongoing fraud? Australian consumers and businesses are actively battling a significant uptick in ...

Austral Foods Launches NiMera an Innovative Day and Night Infant Formula

Austral Foods has launched NiMera, a premium Day and Night Formula for infants, to ensure bottle-fed infants receive the right nutrients at the right time. The scientifically designed formulas aim to closely mirror human milk an...

6 Appropriate Gifts to Surprise Your Business Partner

While there’s no doubt that buying gifts can be very rewarding and fun, it’s not uncommon for the task of gift-giving to come with some stress as well. This is especially true when you have to find the perfect gift for someo...